Prudential Financial Inc. Decreases Stock Holdings in Haemonetics Co. (NYSE:HAE)

Prudential Financial Inc. trimmed its stake in Haemonetics Co. (NYSE:HAE) by 28.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,862 shares of the medical instruments supplier’s stock after selling 16,345 shares during the quarter. Prudential Financial Inc. owned approximately 0.08% of Haemonetics worth $3,191,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Cerity Partners LLC grew its stake in Haemonetics by 31.1% in the 3rd quarter. Cerity Partners LLC now owns 8,855 shares of the medical instruments supplier’s stock worth $712,000 after buying an additional 2,102 shares in the last quarter. FMR LLC raised its stake in shares of Haemonetics by 206.3% during the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock worth $62,257,000 after acquiring an additional 521,640 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Haemonetics by 174.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock worth $1,362,000 after acquiring an additional 10,774 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of Haemonetics by 30.1% in the 3rd quarter. Captrust Financial Advisors now owns 4,248 shares of the medical instruments supplier’s stock valued at $341,000 after purchasing an additional 982 shares in the last quarter. Finally, Paloma Partners Management Co bought a new position in shares of Haemonetics during the 3rd quarter valued at $623,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 1.7 %

Shares of Haemonetics stock opened at $64.09 on Thursday. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 12-month low of $58.80 and a 12-month high of $97.97. The company has a market cap of $3.22 billion, a P/E ratio of 25.23, a PEG ratio of 1.11 and a beta of 0.43. The company’s fifty day simple moving average is $65.42 and its two-hundred day simple moving average is $74.47.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Research analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Raymond James restated a “strong-buy” rating and set a $115.00 price target (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Barrington Research reduced their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JMP Securities lowered their price objective on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, February 7th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Finally, JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Haemonetics currently has a consensus rating of “Moderate Buy” and an average price target of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.